Autism Treatment Market Set to More Than Double by 2030
As the rates of autism spectrum disorder (ASD) continue rising in the United States and around the world, so does the market for treating the immune and brain dysfunction associated with the neurological and developmental disorder that affects one in 36 eight-year-old children in the U.S., with one in six suffering with a developmental disability. […]
First Postpartum Depression Drug Fast Tracked and Licensed by FDA
On Aug. 4, 2023, the U.S. Food and Drug Administration (FDA) fast tracked licensure of the oral prescription medication Zurzuvae (zuranolone), manufactured by Sage Therapeutics, Inc. as a treatment for postpartum depression. Postpartum affects roughly one in seven women and typically begins after childbirth but, for some women, it can begin during later stages of […]
